
New data show EBGLYSS and combo Taltz-Zepbound improve treatment for atopic dermatitis, psoriasis, and obesity.
Eli Lilly presented new data at the 2026 Fall Clinical Dermatology Conference highlighting EBGLYSS (lebrikizumab-lbkz) for moderate-to-severe atopic dermatitis, showing durable disease control with less frequent dosing and reduced topical treatment. ...





